The vaccination drive against coronavirus will kick off on January 16, 2021. The priority will be given to the healthcare workers and the frontline workers, estimated to be around 3 crore, followed by those above 50 years and the under-50 population groups with co-morbidities numbering around 27 crore, the government said on Saturday.
As India gets closer to mass vaccination nation-wide rollout, it must brace up to tackle vaccine misinformation on a war footing.
A second dry run to check the best way to vaccinate people against COVID-19 is taking place across 737 districts in the country today.
The chairman of Bharat Biotech - whose coronavirus vaccine Covaxin was yesterday given 'restricted use in emergency situation in public interest' - hit out today at critics querying the lack of Phase III trial data and others questioning the drug's efficacy.
Speaking during a virtual press conference, Bharat Biotech MD Krishna Ella sought to clear all doubts over the much awaited vaccine against coronavirus and asserted that he has no political connections.
The Drugs Controller General of India (DCGI) has given licensing permission to Hyderabad-based Bharat Biotech to manufacture 'Covaxin' for sale and distribution. The DCGI approval document said the firm can vaccinate children above the age of 12 years during the clinical trial mode.
The Serum Institute of India, the world's largest vaccine manufacturer, has tied up with AstraZeneca to manufacture Covishield, while Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
The Central Licensing Authority on Sunday granted permission to Bharat Biotech to manufacture Covaxin for sale and distribution, hours after the Drug Controller General of India (DCGI) approved the coronavirus vaccine for restricted emergency use.
Bharat Biotech claimed on Sunday that its vaccine generated excellent safety data with robust immune responses to multiple viral proteins that persist.
Drug Controller General of India (DCGI) on Sunday approved Serum Institute of India's 'Covishield' vaccine and Bharat Biotech's 'Covaxin' for emergency use against coronavirus.
Drug Controller General of India (DCGI) on Sunday approved Serum Institute of India's 'Covishield' vaccine and Bharat Biotech's 'Covaxin' for emergency use against coronavirus.
In a significant development, Drugs Controller General of India (DGCI) on Sunday (January 3) formally approved Oxford-AstraZeneca's Covishield and Bharat Biotech's Covaxin for use in India.
Hours after India's drugs regulator approved Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, Union Health Minister Dr. Harsh Vardhan on Sunday called it a "watershed moment" in India’s famed battle against COVID-19.
As India gears up for the world's largest vaccination programme, the Drugs Controller General of India (DCGI) on Sunday quelled rumours surrounding the COVID-19 vaccines regarding impotency, rubbishing such speculations as "absolute nonsense".
The approved vaccines will be first offered to one crore healthcare workers, along with two crore frontline and essential workers and 27 crore elderly, mostly above the age of 50 years with co-morbidities.
Covid-19 vaccines- COVAXIN and COVISHIELD have been cleared for restricted use in emergency situation, DCGI, V G Somani said.
The expert panel has recommended granting permission for restricted emergency use of 'Covaxin' in "public interest as an abundant precaution, in clinical trial mode, especially in the context of infection by mutant strains.
In a significant development, Drugs Controller General of India (DGCI) on Sunday (January 3) formally approved Oxford-AstraZeneca's Covishield and Bharat Biotech's Covaxin for use in India.
The AIDAN has said it is shocked to learn about the recommendation to grant REU approval to Bharat Biotech's COVAXIN in "clinical trial mode" and "specially in the context of infection by mutant strains".
Bharat Biotech on Saturday announced successful recruitment of 23,000 volunteers, and continued progress towards achieving the goal of 26,000 participants for phase-III clinical trial of its coronavirus vaccine 'Covaxin' across multiple sites in India.
Top News
Latest News
